Pexidartinib (PLX3397) is a multi-kinase inhibitor targeting CSF-1R that is FDA approved for the treatment of tenosynovial giant cell tumor, a rare CSF1-driven neoplasm [192]. Here, CSF1 is linked to neoplasm.